Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy

(2019) L. M. Soveri et al.   ACTA ONCOLOGICA

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC

(2019) Fabrice Barlesi et al.   Journal of Thoracic Oncology

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

(2019) Federico Innocenti et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study

(2019) Rui Pedro Marques et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

(2019) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer

(2018) David J. Vaughn et al.   JOURNAL OF CLINICAL ONCOLOGY

Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes—An ESDO Report

(2017) Eric Van Cutsem et al.   Cancers

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

(2016) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Methodological and Reporting Quality of Comparative Studies Evaluating Health-Related Quality of Life of Colorectal Cancer Patients and Controls

(2016) Carlos K. H. Wong et al.   DISEASES OF THE COLON & RECTUM

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

(2016) Dirk Schadendorf et al.   EUROPEAN JOURNAL OF CANCER

Role of targeted therapy in metastatic colorectal cancer

(2016) Yoshihito Ohhara et al.   World Journal of Gastrointestinal Oncology

Symptom Prevalence in Lung and Colorectal Cancer Patients

(2015) Anne M. Walling et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

(2014) S. Venderbosch et al.   CLINICAL CANCER RESEARCH

Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

(2012) K. Cocks et al.   EUROPEAN JOURNAL OF CANCER

Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin

(2012) István Láng et al.   EUROPEAN JOURNAL OF CANCER

Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer

(2009) R.N. Whistance et al.   EUROPEAN JOURNAL OF CANCER

Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

(2008) F. F. Kabbinavar et al.   ONCOLOGIST